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Patients with Limited Volume Metastatic Non-small Cell
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Ravi Salgia, MD, PhD,† Victoria M. Villaflor, MD, Niket Shah, BS,* Philip C. Hoffman,
Steven J. Chmura, MD, PhD,*‡ Philip P. Connell, MD,* Everett E. Vokes, MD,*
Ralph R. Weichselbaum, MD,*‡ and Joseph K. Salama, MD
Introduction: Outcomes data treating patients with oligometastatic
(5 metastases) non-small cell lung carcinoma (NSCLC) with
hypofractionated image-guided radiotherapy (HIGRT) are limited.
Methods: Consecutive oligometastatic NSCLC patients were
reviewed from a prospective database. Patients were included if
all active diseases were treated with HIGRT. Lesions that had
received prior radiation or had radiographic/metabolic resolution
after chemotherapy were not treated with HIGRT. Local control
of all treated lesions, distant control, progression-free survival
(PFS), overall survival (OS), and control of individual lesions
(LeC) were calculated.
Results: Twenty-five patients with median of 2 treated oligometa-
static lesions were included. Median follow-up was 14 months.
Median age was 66 years. Nineteen patients received systemic
therapy before HIGRT and 11 had progressive disease after their
most recent systemic therapy before HIGRT. Median OS and PFS
were 22.7 and 7.6 months. The 18 months local control, distant
control, OS, and PFS were 66.1%, 31.7%, 52.9%, and 28.0%.
Greater than two sites treated with HIGRT, nonadenocarcinoma
histology, prior systemic therapy, and progression after systemic
therapy were associated with worse PFS. Sixty-two individual le-
sions of median size 2.7 cm were treated. For extracranial lesions,
median total and fraction dose were 50 and 5 Gy. Median standard
equivalent dose in 2 Gy fractions for extracranial lesions was 64.6
Gy yielding 18 months LeC of 70.7%. Standard equivalent dose
64.6 Gy increased LeC (p  0.04). Two patients experienced
grade 3 toxicity.
Conclusions: HIGRT for oligometastatic NSCLC provides durable
LeC and may provide long-term PFS in some patients. Future
HIGRT studies should optimize patient selection and integration
with systemic therapy.
Key Words: Non-small cell lung cancer (NSCLC), Oligometasta-
ses, Radiation, Outcomes.
(J Thorac Oncol. 2012;7: 376–381)
Metastasis is the leading cause of cancer death in patientswith lung cancer. Non-small cell lung cancer (NSCLC)
represents 85% of lung cancers (187,000 cases) with greater
than one-half of patients either presenting with or subse-
quently developing metastatic disease.1,2 Patients with meta-
static NSCLC usually receive treatment with either cytotoxic
or targeted systemic agents alone or in combination. Third-
generation chemotherapy doublets, such as cisplatin and
docetaxel, are more effective than prior regimens.3–6 How-
ever, even with the most effective agents, response rates are
generally 30%, and median survival from diagnosis is
approximately 1 year.5,7 For patients who progress after
first-line chemotherapy, additional systemic agents are less
effective with response rates to second-line therapy, ranging
from 7 to 11% with median survivals of 6.7 to 8.3 months.8–11
As most of patients progress, improvements in therapy are
clearly needed.
Patients with metastatic NSCLC do not always present
with widespread metastatic disease. An analysis of metastatic
NSCLC patients demonstrated that 50% of patients presented
with one to five metastatic sites in limited organs. Further-
more, analyses of patterns of progression in metastatic
NSCLC patients reveal up to 64% progress exclusively in
known sites of disease after first-line systemic therapy.12,13
Based on the hypothesized clinical state of oligometastases,
wherein a cancer’s metastatic potential is limited in num-
ber,14,15 there may exist a window when local therapy to all
sites of known metastases can provide durable remission in a
subset of patients. Furthermore, improving systemic therapies
may reduce the microscopic metastatic burden, rendering
patients into a state of induced oligometastases. Although
clinical evidence supporting an oligometastatic state in
NSCLC is relatively limited, long-term survivorship has been
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reported after resection of brain16 and adrenal metastases.17
These data suggest at minimum a progression-free survival
(PFS) benefit may be obtained from metastasis-directed treat-
ment for a subset of oligometastatic NSCLC patients.
Based on these data, and studies reporting that more
than half of such patients would meet inclusion criteria for
hypofractionated radiotherapy at some point during their
systemic treatment,12 we began offering hypofractionated
image-guided radiation therapy (HIGRT) for nonsurgical
metastatic NSCLC patients with extracranial oligometastatic
lesions in 2004. Herein, we report our experience.
PATIENTS AND METHODS
Eligibility
Patients were identified retrospectively from a prospec-
tively maintained database of patients with limited metastatic
disease from a variety of primary tumors treated on or off
protocol using HIGRT. Patients were included in this analysis
if they had histologically or cytologically proven stage IV
(American Joint Committee on Cancer 6th edition) or recur-
rent NSCLC with one to five sites of metastatic and primary
disease. All patients were evaluated by an attending radiation
oncologist to determine eligibility for HIGRT and were
required to receive treatment to all known sites of active
disease. Lesions receiving prior radiation (if radiographically
stable) or with radiographic/metabolic resolution after
chemotherapy were declared inactive and did not receive
HIGRT. This analysis was approved by the University of
Chicago’s institutional review board.
Treatment
Systemic Therapy
Patients received a variety of chemotherapeutic and
targeted agents at the discretion of the treating medical
oncologist usually before HIGRT. The typical interval be-
tween systemic therapy and HIGRT was a minimum of
2 weeks. Chemotherapy was not given concurrently with
HIGRT.
Radiation Therapy
Before HIGRT, all patients were simulated in custom-
made immobilization devices. For nonosseous metastases of
the thorax and upper abdomen, patients underwent contrast-
enhanced computed tomography (CT)-based radiation plan-
ning including four-dimensional (4D) CT scans to allow
visualization and assessment of respiratory-induced tumor
motion. For pulmonary lesions with limited respiratory mo-
tion, an internal target volume (ITV) was generated based on
maximal intensity projection images from the entire respira-
tory cycle of the gross tumor volume. The patient was
subsequently treated free breathing/continuously throughout
the respiratory cycle. For lesions with marked respiratory
motion, end-expiratory respiratory gating was employed.
Maximum intensity projection images were created repre-
senting only the respiratory gating window on which a gating
ITV was contoured representing tumor motion within the
gating window. Diagnostic images (magnetic resonance im-
aging, FDG-PET, triple phase CT, etc.) were anatomically
registered to the planning CT scans routinely to assist with
target delineation. Subsequently for both techniques, the ITV
was expanded 5 to 12 mm to account for setup reproducibility
and lesion location at the treating physician’s discretion to
create the planning target volume (PTV).
A variety of nonoverlapping axial fields and noncopla-
nar fields were combined to achieve the optimal radiation
distribution to tumors while minimizing radiation to sur-
rounding tumor-free organs. Normal tissue tolerances were
compounded from the available literature.18,19 Prescription
doses varied based on inclusion on an in-house single insti-
tution protocol. For patients treated on protocol, each meta-
static lesion was assigned to one of five anatomic regions
based on potential normal tissue complication, which deter-
mined the dose escalation schedule (lung, liver, abdominal,
head and neck, and extremity). The starting dose for all sites
was 24 Gy delivered in three 8 Gy fractions and escalated in
2 Gy per fraction increments using a standard 3  3 schema.
Protocol patients received three fractions of radiotherapy
separated by a minimum of 48 hours and a maximum of 192
hours. For patients treated off protocol, radiation planning
techniques were identical to those treated on protocol. We
used a previously established 10-fraction schedule20–22 deliv-
ering a cumulative dose of 50 Gy in 5 Gy daily radiation
fractions for most patients. Intracranial radiosurgery for brain
metastases was performed in the usual fashion with doses per
standard guidelines.23
Each treatment was personally supervised by an attend-
ing physician. Before each treatment, daily image guidance
with gated kilovoltage (kV) images and/or nongated kV cone
beam CT scans was acquired after the patient was placed in
the treatment position. Appropriate adjustments were made to
ensure that nearby bony anatomy correlated to the planning
CT scan. Most target lesions could also be visualized on kV
cone beam CT scan to confirm that they were encompassed
by the planning target volume.
Patients returned for follow-up every 2 weeks for the
first month, monthly for 3 months, and then every 3 months
thereafter. Appropriate imaging studies (whole-body CT
and/or FDG-PET) were performed 1 month after the comple-
tion of treatment and then every 3 months thereafter. Mag-
netic resonance imaging was routinely used to assess intra-
cranial response. Each metastatic lesion was considered
independently and assessed for response using axial unidi-
mensional measurements per RECIST criteria. Patterns of
first and cumulative progression were determined by follow-
ing all target and nontarget lesions (primary tumors and all
metastatic sites) on all follow-up imaging studies. Toxicity
was scored using the Common Toxicity Criteria version 3.0.
Statistics
Patient- and lesion-based analyses were performed. For
the patient-based analysis, the following end points were
evaluated: PFS defined as the time to progression or death,
overall survival (OS), local control (LC) defined as no pro-
gression of all HIGRT-treated metastases within a patient,
and distant control (DC) defined as progression outside of
treated lesions. Progression in a lesion not treated with
HIGRT but with another modality before the first HIGRT
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course (i.e., standard fractionation radiotherapy) was not
scored as distant progression. However, these were included
in the PFS calculation. The time to reach each end point was
defined from the start of HIGRT to the time of progression/
death. Six patients underwent a second course of HIGRT for
limited distant progression. The patient-based analysis fo-
cused only on the first course. For lesion-based analysis, the
only end point evaluated was lesion control (LeC), which was
defined as no increase in lesion size 20% on single dimen-
sional axial measurement. All lesions were included in LeC
regardless of whether they were treated during the first or a
subsequent course of HIGRT. All end points were estimated
using the Kaplan-Meier method.
Univariate analysis (UVA) was performed using the
log-rank test. A p value 0.05 was considered statistically
significant for UVA. However, given the small patient num-
bers and the heterogeneity of the patient population, subset
analyses are considered exploratory. Multivariate analysis
was not performed because of the limited number of events.
RESULTS
Twenty-five patients with oligometastatic NSCLC met
the inclusion criteria. Eleven patients were treated on proto-
col from December 20, 2004, to July 9, 2008. Fourteen
patients were treated off protocol, 12 of whom were treated
after July 9, 2008. Patient and tumor characteristics are given
in Table 1. The median age was 66 years. Eleven patients had
adenocarcinoma and 14 had other NSCLC histologies. Fif-
teen patients received HIGRT after presenting with metastatic
disease (stage IV) as their initial diagnosis, while 10 initially
had stage III or lower disease and subsequently developed
metastases that prompted HIGRT.
Treatment details can be found in Table 2. Nineteen
(76%) patients received systemic therapy before HIGRT,
usually one regimen comprising two systemic agents. Sixteen
patients (84%) received a platinum-based doublet as part of
their prior systemic therapy, most commonly carboplatin and
paclitaxel (10 patients). Eighteen patients received HIGRT to
all sites of disease and seven received treatment only to active
(growing and/or PET-positive) disease sites. A median of 2
(range, 1–5) oligometastatic lesions were treated per patient
during their first course of HIGRT. The treatment sites are
listed in Table 1.
HIGRT was well tolerated with acceptable toxicity.
Five patients experienced grade 2 toxicity including two
patients with chest wall pain (one from rib fracture and one
without radiographic evidence of fracture), two patients with
acute dysphagia, and one patient with fatigue. Two patients
experienced grade 3 toxicity: one patient had fatigue inter-
fering with activities of daily living, which was significantly
improved within 2 months, and another patient had radiation
pneumonitis requiring steroids and a hospital admission.
With a median follow of 14 months, 7 of 25 patients
(28%) had no evidence of progression. Five of these seven
patients had more than 15 months of follow-up without
evidence of progression (range, 15.8–25.7 months). Six pa-
tients experienced in-field local progression. One patient of
these six had isolated local progression in a HIGRT-treated
lesion, and the remaining five patients had combined distant
and local progression (in all cases, local progression was
documented at the same time or after distant progression).
The 12 and 18 months LC of all treated lesions for a patient
undergoing their first course of HIGRT were 74.4% (95%
confidence interval [CI] 51.1–88.9%) and 66.1% (95% CI
41.1–84.4%), respectively. The 12 and 18 months DC rates
were 45.3 (95% CI 26.7–65.2%) and 31.7% (95% CI 16.1–
53.0%), respectively (Table 3). Seventeen patients experi-
enced distant progression, including 12 patients without ev-
idence of local progression. Six of these patients had limited
distant progression and were treated with a second course of
HIGRT. Seventeen patients received systemic therapy during
the follow-up period after HIGRT. In 15 of these patients,
systemic therapy was initiated after documented post-HIGRT
disease progression.
Median OS and PFS were 22.7 and 7.6 months, respec-
tively. The 12 and 18 months OS were 81.1% (95% CI
58.7–92.9%) and 52.9% (95% CI 28.6–75.8%), respectively.
Corresponding PFS values were 42.0 (95% CI 24.1–62.2%)
and 28.0% (95% CI 13.5–49.4%), respectively (Table 3,
Figures 1A, B). On UVA, more than two sites treated with
HIGRT (p  0.0020), prior systemic therapy (p  0.025),
progressive disease after prior systemic therapy (versus con-
TABLE 1. Patient and Tumor Characteristics
Characteristic
No. of patients 25
Age, yr (range) 66.2 (43.5–79.2)
Histology
Adenocarcinoma 11
Squamous cell 6
Carcinoma
Large cell 2
Other or NSCLC NOS 6
Initial stage
I 3
II 1
III 6
IV 15
Lesion size (cm)
Mean 3.2
Median (range) 2.65 (0.6–9.6)
Interquartile range 1.8–4.2
Lesions treated per patient
Median (range) 2 (1–5)
Lesion location (n  62)
Lung 28
Adrenal gland 8
Lymph node 10
Liver 5
Brain 5
Bone 4
Spleen 1
Muscle 1
NSCLC, non-small cell lung cancer; NOS, not otherwise specified.
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solidative HIGRT for partial response or stable disease) (p 
0.04), and nonadenocarcinoma histology (p  0.014) were
associated with worse PFS. Treatment of active disease only
(i.e., HIGRT omitted for sites of radiographically evident
disease that was not growing or PET-positive) (p  0.77),
treatment off protocol (p  0.94), history of prior radiother-
apy (p  0.58), HIGRT for metachronous metastases (pre-
sented with initial stage I–III) (p  0.18), intracranial disease
at HIGRT (p  0.07), and sum of the maximum axial
diameter of each treated lesions  median (p  0.095) were
not significant. For patients who experienced LC of all treated
lesions, the 12 and 18 months OS were 88.2 (95% CI
62.8–97.2) and 68.0% (95% CI 37.2–88.3) compared with
66.7 (95% CI 26.7–91.2) and 22.2% (95% CI 3.3–71.7) for
those with local failure (p 0.28, log-rank). Importantly, this
suggests that ability to attain LC may improve survival in
patients with metastatic NSCLC.
Lesion-based analysis revealed that 62 individual oli-
gometastatic lesions were treated. Three lesions were ex-
cluded from analysis, two because of lack of follow-up
imaging and one because it represented reirradiation of the
primary tumor site. The median lesion size was 2.65 cm
(range, 0.6–9.6 cm). The 12 and 18 months LeC for all
treated lesions were 85.0% (95% CI 70.0–93.3) and 65.3%
(95% CI 49.4–81.7), respectively.
For extracranial sites, the median total dose was 50 Gy
(range, 24–70 Gy) and the median dose per fraction was 5 Gy
(range, 3.5–14 Gy). The 12 and 18 months LeC were 86.4%
(95% CI 70.6–94.4%) and 70.7% (95% CI 51.7–84.4%),
respectively, for extracranial oligometastatic sites. The stan-
dard equivalent dose (SED) in 2 Gy fractions was calculated
for all extracranial lesions.24 The median SED for extracra-
nial lesions was 64.6 Gy (range, 37.6–73.9 Gy). The 50 Gy
in 5 Gy fraction regimen represents an SED in 2 Gy fractions
of 64.6 Gy. For three-fraction treatment regimens, frac-
tion sizes 14 Gy yield an SED above 64.6 Gy, while
fraction sizes 12 Gy yield SED below 64.6 Gy. There was
improved (p  0.04) LeC with SED 64.6 Gy (Figure 2).
The 12 and 18 months LeC were 91.6% (95% CI 70.0–
98.3%) and 83.3% (95% CI 56.1–95.0%) for SED 64.6 Gy
versus 78.6 (95% CI 50.6–92.8%) and 52.4% (95% CI
26.1–77.2%) for SED 64.6 Gy. There was no relationship
between maximum axial lesion diameter greater than the
median of 2.65 cm and LeC (p  0.76). For the five
intracranial lesions, all patients received whole brain radiation
therapy followed by stereotactic radiosurgery to 18 Gy in one
fraction. The 12 months LeC was 80% (95% CI 31.1–97.2%).
DISCUSSION
To the best of our knowledge, this is the first report of
patients with limited volume metastatic NSCLC treated to all
sites of active cancer with HIGRT. Our data show that
HIGRT for selected patients can be delivered safely and is
associated with promising clinical outcomes. Our results are
consistent with prior surgical studies, which have demon-
strated some long-term survivors among patients with meta-
static NSCLC undergoing resection of metastatic disease. For
example, Wronski et al.16 reported 5-year survival rates of
13% in a series of 231 patients undergoing resection of
NSCLC brain metastases. Tanvetyanon et al.17 recently per-
formed a pooled analysis of 10 publications including 112
patients undergoing adrenalectomy for metastatic NSCLC
and reported 5-year OS of 25 to 26%. These promising
outcomes with metastasectomy influenced our decision to
offer nonsurgical local therapy to patients with limited vol-
ume metastatic disease.
We began to offer HIGRT for patients with limited
volume NSCLC metastases after analyses demonstrated that
NSCLC patients commonly present with only a few sites of
metastases and that the majority of these patients progress
first in these known metastatic sites.12,13 These data suggest
that at least a subset of stage IV NSCLC exhibit character-
istics of the oligometastatic state. A tenet of the oligometa-
TABLE 2. Treatment Details
Radiation therapy
Fractionation schemes (total dose/number
of fractions)
Extracranial No. of lesions
50 Gy/10 28
24 Gy/3 9
30 Gy/3 8
42 Gy/3 6
70 Gy/20 4
36 Gy/3 2
Intracranial
18 Gy/1  WBRT 5
Median SED in 2 Gy fractions for extracranial
lesions (range)
64.6 Gy (37.6–73.9 Gy)
Systemic therapy
Prior systemic therapy No. of patients
Yes 19
No 6
Median prior systemic linesa (range) 1 (1–3)
Median prior systemic agentsa (range) 2 (1–4)
SED is the standard equivalent dose which converts hypofractionated radiation into
an equivalent dose using standard 2 Gy fractions.
a In subset of patients receiving prior systemic therapy.
WBRT, whole brain radiation therapy.
TABLE 3. Patient Outcomes
12 mo (95% CI) 18 mo (95% CI)
Outcome
Overall survival 81.1% (58.7–92.9%) 52.9% (28.6–75.8%)
Progression-free survival 42.0% (24.1–62.2%) 28.0% (13.5–49.4%)
Distant control 45.3% (26.7–65.2%) 31.7% (16.1–53.0%)
Local controla (patient
based)
74.4% (51.1–88.9%) 66.1% (41.1–84.4%)
Lesion controlb (lesion
based)
85.0% (70.0–93.3%) 65.3% (49.4–81.7%)
a Local control requires all treated lesions within an individual patient to be
controlled.
b Lesion control requires an individual lesion to be controlled.
CI, confidence interval.
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static state is that local therapy may improve PFS and
potentially render patients with long-term disease-free sur-
vival. In the current study, a trend toward improved survival
was observed in patients who attained LC of all HIGRT-
treated lesions compared with those with local progression.
Outcomes for patients included in this series are en-
couraging, especially in light of the fact that 19 patients
(76%) previously received first-line systemic therapy and 13
(52%) had documented progression on their most recent
systemic regimen before HIGRT. In addition, the median age
of our patients was older than patients included on most
randomized trials of first-line systemic therapy.4,5,8 Despite
these unfavorable characteristics, the OS and PFS seem
improved compared with outcomes with first- or second-line
systemic therapy alone. Because 15 of 17 patients received
post-HIGRT systemic therapy after developing disease pro-
gression, the PFS results are not skewed by effects of addi-
tional systemic therapy. While these patients represent a
select subset based on their eligibility for HIGRT, other
investigators have reported that more than 50% of patients
presenting to a university hospital with advanced NSCLC
meet such criteria at some point during their disease course.12
One of our primary goals of offering HIGRT for limited
volume metastatic NSCLC was to prolong PFS by offering
metastasis-directed therapy with limited toxicity—in effect
offering another “line” of therapy. Further follow-up is
needed to determine the duration of long-term control as their
median follow-up is 14 months (range, 3.6–31.7 months).
However, the fact that 28% of patients are without evidence
of disease is promising and suggests that properly selected
patients can benefit from nonsurgical metastasis-directed
therapy. In addition, toxicity was fairly mild and infrequent in
patients treated with HIGRT on our study, which is an
important consideration that should be weighed against the
toxicity of additional lines of chemotherapy.
Our study is limited by the relatively small sample size
hindering the power to accurately evaluate the influence of
patient- and treatment-related factors on outcome. In addi-
tion, metastatic NSCLC is a heterogeneous population, and
the efficacy of HIGRT is likely influenced by disease burden,
sites of metastases, age, performance status, and number of
prior systemic therapy regimens/response to prior systemic
therapy. Furthermore, our study population was heteroge-
neous as it included patients with both synchronous and
metachronous metastatic disease who received a variety of
systemic and local therapies before HIGRT treatment. Al-
though synchronous metastatic presentation, receipt of prior
radiotherapy, and treatment of active disease only were in-
significant on UVA, these results must be interpreted with
caution due to the small sample size. Finally, different dose/
fractionation schemes were used, although we attempted to
compensate for this using the SED in 2 Gy fractions. In the
context of these limitations, larger prospective studies in this
patient population are warranted to determine which subsets
of patients with oligometastatic NSCLC are most likely to
benefit from HIGRT.
Currently, the North Central Cancer Treatment Group
is investigating the role of consolidation radiation therapy by
randomizing patients with limited volume NSCLC to obser-
vation versus radiation to known metastatic sites after four to
six cycles of chemotherapy. This study will assess the role of
the addition of HIGRT to systemic therapy in the upfront
treatment setting.
CONCLUSIONS
This study demonstrates that HIGRT for oligometa-
static NSCLC is associated with minimal toxicity and a high
rate of LC for treated lesions. Short-term survival rates are
favorable compared with studies using systemic therapy
alone. Further follow-up is needed to determine whether
long-term PFS and OS can be achieved in this patient popu-
lation. Prospective studies are required to more accurately
determine the safety and efficacy of HIGRT in oligometa-
static NSCLC and to better identify subpopulations of pa-
tients who are most likely to benefit from local therapy.
FIGURE 1. A, Overall survival for all pa-
tients with 95% confidence intervals (CI). B,
Progression-free survival for all patients with
95% CI.
FIGURE 2. Extracranial lesion control for patients with stan-
dard equivalent dose 64.6 Gy in 2 Gy fractions (bold line)
and 64.6 Gy (thin line).
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